Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| This position provides us strong ability to continue our investments in the development of ivonescimab |
| We believe that this study data is very promising |
| As Bob discussed, I remain incredibly enthusiastic about ivonescimab and its potential, the strength of team Summit and the accomplishment we have made just one year into our partnership with Akeso |
| We are fortunate to have such a strong partnership and ongoing collaboration with Akeso, including the ability to leverage data generated for ivonescimab across multiple solid tumors studies in support of Summit's own clinical development in our licensed territories, the U.S., Canada, Europe and Japan |
| We have a strong cash position and we have extended our cash runway going into 2025 |
| Team Summit's conviction and our belief in ivonescimab continues to drive our progress forward in our efforts to collapse time and reach critical milestones faster |
| Echoing the sentiment, we're very pleased with the speed of execution of team Summit and our partners at team Akeso, in the development of ivonescimab |
| Maky and I are appreciative and honored to be leading team Summit, where our accomplished leaders and team members have unparalleled track records for high-speed execution that delivers intended results |
| We believe ivonescimab has the potential to achieve this |
| This extension, coupled with our strong cash position, provides funding to make significant progress in the development of ivonescimab, as well as covering some of the key milestones that Maky spoke about |
| It has been just one year since we closed on our partnership with Akeso and I'm very proud of the accomplishments and impressive progress team Summit has made in this period of time |
| So there's a number of different aspects where we think we can have an advantage |
| So, in summary, we're excited about the potential of ivonescimab, and have made a lot of progress in its development during 2023 |
| We have a strong cash position with $160 -- $186 million in cash and investments as of end of year 2023 |
| We approach these efforts with the intent of helping patients improve quality of life, increase the potential duration of life, and resolve serious medical needs in line with Summit's strongly held mission statement |
| In addition to progressing our internal development program, we appreciate a high level of enthusiasm we are hearing from key opinion leaders and other physician leaders for what ivonescimab can do to make significant positive difference in and outside of lung cancer |
| As mentioned earlier, we also plan to complete enrollment in a HARMONi study in the second half of this year, providing momentum towards a submission for ivonescimab in our licensed territories |
| So I think you should view it positively, even the fact that, as you know, the Chinese version of the HARMONi study enrolled 320 patients, approximately 320 patients, of which about 50 of them received a first or second generation TKI, which is still considered standard care in China |
| In both settings, ivonescimab has had an acceptable safety profile in the Phase 2 clinical trial |
| We continue to progress as well as collapse time in order to achieve our aggressive but realistic goals for ivonescimab to ultimately improve existing treatment options to the many lung cancer patients with serious ongoing unmet needs |
| This experience and our expertise are foundational to achieving our goals for 2024 and beyond, continuing to execute on our Phase 3 clinical trials while expanding our clinical development plan |
| In the presence of PD-1, VEGF affinity increases by over fourfold |
| Our goal is to improve upon previously established efficacy standards in addition to side effects and safety profile associated with these two targets |
| From a HARMONi-3 perspective, we just began enrollment in the fourth quarter of 2023, and we've yet to give the guidance in terms of when that will complete, but we're currently enrolling and are excited about moving quickly in that setting as well |
| And so we think that that adds sort of value to patients and important for patients |
| HARMONi and HARMONi-3 represent the first step in our strategy and we believe ivonescimab has potential in both additional non-small cell lung cancer indications and in other solid tumors |
| And we believe that the safety profile demonstrated to date in the Phase 2, as well as large database, is supportive of developing a VEGF that has been attached to PD-1 with cooperative binding in this space |
| And so PFS seems to track pretty well with OS |
| So I think the data should correlate pretty well for the global study |
| Ivonescimab's cooperative binding qualities lead to the potential to steer more drugs to the tumor and tumor microenvironment |
| Statement |
|---|
| There was a concern about bleeding risks early on and therefore, I think lung cancer patients in the squamous setting never really realized the potential of anti-VEGF |
| Please refer to our SEC filings for information about these risks and uncertainties |
| And what's interesting, Hartaj, is the squamous non-small cell lung cancer population, or that space has become a lot less crowded recently |
Please consider a small donation if you think this website provides you with relevant information